Vigil Neuroscience (NASDAQ:VIGL) Rating Reiterated by Wedbush

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report)'s stock had its "outperform" rating restated by investment analysts at Wedbush in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $22.00 target price on the stock. Wedbush's target price suggests a potential upside of 482.01% from the stock's previous close.

Other equities research analysts have also issued reports about the stock. JMP Securities reiterated a "market outperform" rating and set a $23.00 target price on shares of Vigil Neuroscience in a research report on Thursday, April 18th. HC Wainwright reiterated a "buy" rating and issued a $24.00 price objective on shares of Vigil Neuroscience in a report on Wednesday.

Vigil Neuroscience Stock Up 18.5 %

Shares of NASDAQ:VIGL traded up $0.59 during midday trading on Wednesday, reaching $3.78. 531,801 shares of the company traded hands, compared to its average volume of 99,420. The firm's fifty day moving average price is $3.08 and its two-hundred day moving average price is $3.72. The firm has a market capitalization of $142.07 million, a price-to-earnings ratio of -1.77 and a beta of 1.87. Vigil Neuroscience has a 12 month low of $2.50 and a 12 month high of $11.11.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings results on Tuesday, March 26th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.01). Analysts forecast that Vigil Neuroscience will post -2.56 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Vigil Neuroscience stock. Strs Ohio purchased a new position in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 8,200 shares of the company's stock, valued at approximately $27,000. Institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.